Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Thuy Doan, MD, PhD
Headshot of Thuy Doan
Thuy Doan

Description

Summary

This is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility criteria will be randomized to receive MDS testing results or not to receive MDS testing results. All patients will receive standard-of-care testing to guide management. Enrolled patients will be followed at week 2, week 3-6 (randomization visit), and at 4 weeks after the randomization visit. The proportions of patients who received the appropriate therapy and the proportions of patients with improved outcome will be compared between arms. Patient quality of life, MDS performance, and the provider certainly of belief will be collected.

Keywords

Uveitis Infectious Disease Metagenomic deep sequencing Intraocular infection MDS Communicable Diseases Infections Metagenomic Deep Sequencing (MDS)

Eligibility

You can join if…

Open to people ages 18 years and up

  • Presumed infectious anterior uveitis, or intermediate uveitis, or posterior uveitis, or panuveitis
  • Presumed post-operative endophthalmitis
  • Unilateral or bilateral
  • 18 years and older

You CAN'T join if...

  • Insufficient specimen for MDS
  • Age < 18 years of age
  • Pregnancy
  • Unable to consent

Location

  • University of California San Francisco (UCSF) accepting new patients
    San Francisco California 94158 United States

Lead Scientist at UCSF

  • Thuy Doan, MD, PhD
    Associate Professor, Proctor Foundation, Chancellor/EVC/FAS. Authored (or co-authored) 85 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05286203
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated